Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from $3.5635 billion a year earlier. Diluted EPS was $3.22 versus $3.12, while adjusted EPS was $4.78, up 14.5% from $4.18. Operating cash flow was $563.8 million, compared with $387.2 million.
Labcorp raised its 2026 enterprise revenue growth guidance to 5.9% to 6.7% and adjusted EPS guidance to $18.30 to $18.70; the respective midpoints increased 50 basis points and 18 cents. It received FDA approval for PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma. Labcorp acquired MLM Medical Labs and signed three additional acquisition agreements after quarter-end, subject to regulatory approvals and customary closing conditions; the four transactions are expected to be accretive to adjusted EPS in year one and return cost of capital by year three. It announced a $0.72-per-share quarterly cash dividend, payable December 11, 2026, to stockholders of record November 24, 2026.
Labcorp Holdings Inc. (LH) declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.
Labcorp Holdings Inc. (LH) will release its third-quarter 2026 financial results before the market opens on October 28, 2026, and host a webcast at 9:00 a.m. ET that day. The results and accompanying financial information will be posted on its investor relations website. A webcast replay will be available there approximately two hours after the live event concludes and for one year.
Labcorp Holdings Inc. (LH) reports that the Centers for Medicare & Medicaid Services released preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 under the Protecting Access to Medicare Act, which the company believes rely on unrepresentative market data and would impose steep annual reimbursement cuts.
Labcorp states it had already factored continued PAMA-related reimbursement pressure into its 2026–2029 long-term outlook announced on September 10, 2026 and is reaffirming that outlook: compound annual revenue growth of 5%–8%, adjusted operating margin expansion of 75–150 basis points by the end of 2029, compound annual adjusted EPS growth of 8.5%–11.5%, and compound annual free cash flow growth in line with adjusted earnings growth.
The company supports the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act, is continuing to evaluate the CMS payment rates, and expects to provide additional information on their impact when issuing 2027 financial guidance in February 2027. The growth metrics discussed are non-GAAP measures, which Labcorp presents as supplements to GAAP results.
Labcorp Holdings Inc. (LH) hosted its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a detailed long-term outlook through 2029. For 2026, Labcorp continues to target enterprise revenue of $14.71–$14.83 billion, implying 5.4%–6.3% growth versus 2025, driven by Diagnostics Laboratories revenue of $11.45–$11.53 billion and Biopharma Laboratory Services revenue of $3.27–$3.30 billion. Adjusted EPS guidance remains $18.10–$18.55, up 10.1%–12.8% year over year, with free cash flow of $1.24–$1.36 billion. Labcorp also reiterated its 2026–2029 long-term framework of 5%–8% compound annual revenue growth, 8.5%–11.5% compound annual adjusted EPS growth, adjusted operating margin expansion of 75–150 basis points by 2029, and free cash flow growth in line with adjusted earnings, supported by technology-enabled efficiency programs and disciplined capital deployment.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Oyegunwa Akinbolade reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive vice president, chief information officer and chief technology officer Akinbolade Oyegunwa received a grant of 750 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and vests in three equal annual installments beginning on September 1, 2027. After this award, Oyegunwa holds an aggregate of 2,940 Restricted Stock Units directly.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Meltzer Jonathan C reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive vice president and chief operating officer Jonathan C. Meltzer received a grant of 900 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and will vest in three equal annual installments beginning on September 1, 2027.
After this grant, Meltzer holds an aggregate of 3,594 Restricted Stock Units, representing potential future shares of Labcorp common stock if the vesting conditions are satisfied.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Vaughn Bryan T reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive officer Bryan T. Vaughn, EVP and President, Diagnostics, received a grant of 1,500 Restricted Stock Units on September 1, 2026. Each unit represents the contingent right to receive one share of common stock and vests in three equal annual installments beginning on September 1, 2027. Following this award, Vaughn holds an aggregate of 5,204 Restricted Stock Units, all reported as directly owned.
LABCORP HOLDINGS INC. (symbol: LH) is the issuer of record for a Form 4 filing submitted to the SEC. Caveney Brian J reported acquisition or exercise transactions in this Form 4 filing.
LABCORP HOLDINGS INC. (LH) reported that executive officer Brian J. Caveney, EVP, President of BLS, CMO & CSO, received a grant of 3,000 Restricted Stock Units on September 1, 2026. Each unit represents a contingent right to receive one share of Labcorp common stock and vests in three equal annual installments beginning on September 1, 2027.
After this grant, Caveney holds a total of 7,170 Restricted Stock Units directly. No Rule 10b5-1 trading plan is reported in connection with this award.
Labcorp Holdings Inc. (LH) announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 11:30 a.m. ET. A live audio webcast will be accessible through Labcorp’s investor relations website and archived for 180 days.
Labcorp describes itself as a global provider of innovative and comprehensive laboratory services, with nearly 71,000 employees serving clients in about 100 countries, supporting more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performing over 750 million tests annually.